Pioneering Targeted Gene Expression For Cancer and Vaccines

Cancer therapy requires a careful balance, maximizing therapeutic efficacy while minimizing patient toxicity. The ideal cancer treatment would direct therapy selectively to tumor cells while sparing normal cells and tissues. PhageNova Bio has developed a targeted gene delivery vector that accomplishes this goal. The company intends on completing pre-clinical and IND-enabling requirements, manufacturing efforts, and transition quickly into a first-in-human clinical trial.

PhageNova Bio Highlights

Proprietary, first in class, site-specific targeted gene expression technology initially targeting solid tumors and COVID-19

Targeted Gene Expression

Enabled by AAV genomic components within an engineered ligand-directed bacteriophage genome (AAVP)

PNB-001

Lead cancer asset for solid tumors undergoing enabling efforts, pivotal toxicology, and GMP manufacturing as part of an IND initiative

PNB-V01 platform

Broad phage-based vaccination initially targeting COVID-19 undergoing evaluation with proof-of-concept expected 2H21

Intellectual Property

Broad intellectual property protection established; recently filed patent applications

Manufacturing

Scalable, cost-effective, rapid manufacturing capabilities for different targeting motifs and payloads; partnered with leading biologic CMO

Financing

Raised >$8M in equity financing since 2016 and >$10M in federal and private grants.

Catalysts

IND filing of PNB-001 for solid tumors; relaunch of two active INDs for prostate cancer and obesity; near-term data of COVID-19 vaccine strategy; pipeline validation for numerous targets; and new intellectual property grants and filings